N-Acetyl-Cysteine (NAC)

NAC is subtle for most users. It's not a stimulant, not a mood lifter, not a focus enhancer in any acute felt sense. Onset to felt effect is 2-6 weeks of consistent dosing for the psychiatric/cognitive endpoints; acute effects (hangover prevention, post-paracetamol) are within hours.

What users sometimes notice:

• Less obsessive/repetitive thinking — quietest mental loop, fewer intrusive thoughts, easier disengagement from compulsive patterns. This is the OCD/BFRB signal expressed sub-clinically.
• Reduced cravings — alcohol, sugar, addictive substances. Often noted by users who weren't seeking it.
• Slightly less inflammation — less puffy, fewer canker sores, faster recovery from minor illness.
• Cleaner morning after drinking — less hangover at lower alcohol intakes; NAC pre-bed + hydration is the canonical biohacker hangover stack.
• Sulfur burp / eggy taste — universal at ≥1200 mg, especially on empty stomach. Resolves with food; some brands buffer this with bicarbonate or use enteric coating.
• Slightly more mucus thinning — runnier post-nasal drip during cold, easier productive cough. The mucolytic mechanism manifesting.

What it does NOT feel like:

• Not a nootropic in the cognitive-sharpening sense. Don't expect Tuesday-afternoon-different.
• Not anxiolytic, not euphoric, not sedating.
• Not a replacement for sleep or stimulants.

For Dylan specifically, the most likely felt benefits at 1200 mg/day are: (1) marginal post-sparring brain-fog reduction, (2) general "running a little cleaner" sensation, (3) fewer canker sores / faster cold recovery. Effects are insurance-tier, not feel-tier. The evidence-based reason to take it is the mechanism + biomarker + animal data, not the subjective experience.

• Tolerance buildup: minimal to none. Mechanism is substrate-replenishment (cysteine → GSH) and direct chemical scavenging — neither downregulates with chronic dosing. The xCT antiporter mechanism could theoretically adapt but no human data shows tolerance to NAC's psychiatric effects across 6-24 month trials.
• Recommended cycle: None needed for daily use. Continuous use at 1200 mg/day is the standard clinical pattern and matches V4.
• Reset protocol: Not applicable. Some biohackers cycle 5 days on / 2 off "to preserve hormesis" but there's no evidence this matters at supplement doses. The endurance-adaptation-blunting concern (see B-tier) might justify peri-workout omission for endurance-trained athletes; less concern for MMA.
• Stopping protocol: No tapering needed. Plasma + tissue levels return to baseline over 1-2 weeks.

Synergistic with

• glycine: GSH is gamma-Glu-Cys-Gly. Cysteine is rate-limiting in most tissues, but glycine becomes co-limiting in older adults and during chronic illness (Sekhar 2011; the GlyNAC research line — Premranjan Kumar, Baylor College of Medicine, 2020-2025 trials at 100 mg/kg cysteine + 100 mg/kg glycine in older adults). Co-supplementation produces larger GSH increases than either alone. Dylan's V4 includes 3 g glycine via NOW Foods Glycine (currently flagged for replacement with L-tryptophan in V5; if glycine drops out, NAC's GSH-synthesis efficiency may decrease modestly — worth flagging). Plain glycine at 1-3 g/day with NAC is the simplest GlyNAC-style stack. Dose ratio in trials is typically 1:1 by weight cysteine:glycine, but for healthy young adults the ratio is less critical because endogenous glycine is sufficient.

• curcumin (V4 — Doctor's Best Curcumin Phytosome 500 mg): Both anti-inflammatory, both Nrf2 activators, both hit microglial NF-κB. Convergent on neuroinflammation. Stack in same morning dose. Mechanism overlap is partial; combined effect is additive, not redundant.

• astaxanthin (V5 add): Astaxanthin protects mitochondrial + neuronal membranes from lipid peroxidation; NAC replenishes the GSH pool that recycles oxidized vitamin E and supports glutathione peroxidase. Layered antioxidant defense — astaxanthin guards membranes, NAC guards cytosol/mitochondrial matrix. Strongly synergistic for an MMA athlete with subconcussive impact. This is part of the highest-leverage brain-protection trio in V4/V5: NAC + astaxanthin + DHA.

• omega-3 / DHA (V4 — Carlson Super DHA Gems 2 g): DHA is the most peroxidation-vulnerable fatty acid in brain membranes. NAC + GSH protects DHA from oxidation; astaxanthin also covers this. Triad mechanism — NAC + DHA + astaxanthin is the cleanest membrane-protection set.

• vitamin C (V4 — CGN 500 mg): Vitamin C regenerates oxidized vitamin E; NAC regenerates GSH which regenerates vitamin C. Network antioxidant cycle. Already in V4 — no change needed.

• magnesium (V4 — Magtein + Mg Glycinate): NMDA receptor magnesium block + NAC's xCT-mediated glutamate reduction = layered protection against glutamate excitotoxicity. Particularly relevant for post-impact protection.

• agmatine: Direct NMDA antagonist + iNOS inhibitor + neuroprotective in TBI models. Mechanistic overlap with NAC's glutamate axis but different molecular target. Both daily-safe; layered protection.

• alcohol pre/post protocol (anecdotal but mechanistic): Alcohol metabolism via ADH/ALDH depletes hepatic GSH and produces acetaldehyde. NAC 600-1200 mg pre-drinking + 1200 mg morning-after restores GSH and helps clear acetaldehyde. Not relevant to Dylan (zero alcohol baseline) but worth noting for completeness.

Avoid stacking with

• Nitroglycerin / organic nitrates (isosorbide mononitrate/dinitrate): NAC potentiates nitrate-induced vasodilation, can cause severe hypotension + headache. Documented interaction. Not relevant to Dylan but absolute contraindication for cardiac patients on nitrates.

• Activated charcoal (acute poisoning context): NAC binds activated charcoal, reducing absorption. In paracetamol overdose, charcoal and NAC are spaced apart by hours. Not a daily-stack concern.

• Carbamazepine, antipsychotics, antiepileptics — theoretical: NAC can shift glutamate tone; in patients on glutamate-modulating drugs, monitor. No documented bad interactions but worth flagging for psych populations.

• Anticoagulants (warfarin, DOACs) at high NAC doses: Theoretical antiplatelet potentiation. Sub-clinical at 1200 mg/day. Not relevant to Dylan.

• Endurance-adaptation training contexts (cyclists, marathoners): Some evidence NAC dosed peri-workout blunts the ROS signal needed for mitochondrial biogenesis adaptation. Not a strict "avoid" but worth knowing if endurance is the primary training goal. Less concern for MMA / mixed energy systems.

Neutral / safe co-administration

• All V4 stack components: NAC is already integrated. No interactions with citicoline, magnesium glycinate + threonate, DHA, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C, creatine.
• All V5 planned stack additions: modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, taurine, astaxanthin, l-tryptophan — no known or mechanistically-expected interactions.
• Caffeine — no interaction.
• Most prescription drugs — NAC is not a CYP enzyme inducer/inhibitor at supplement doses.

• Nitroglycerin / nitrates: Major interaction. Severe hypotension + headache. Avoid combination.
• Activated charcoal: Binds NAC; space by 2+ hours.
• Anticoagulants: Theoretical mild antiplatelet effect; no bleeding events at supplement doses.
• Antihypertensives: Mild additive hypotensive effect possible at high NAC doses; not relevant at 1200 mg/day.
• Carbamazepine: NAC can lower carbamazepine levels in some case reports. Monitor if combining.
• Cisplatin / chemotherapy: NAC may protect normal tissue from chemo-induced oxidative damage but theoretical concern about reducing tumor-killing efficacy. Specialist territory; do not self-combine during oncology treatment without oncologist clearance.
• CYP enzymes: NAC is not a notable CYP inducer or inhibitor. No relevant interactions with modafinil, bupropion, or other CYP-metabolized stack drugs at supplement doses.
• Contraceptives: No documented interaction.
• Paracetamol (therapeutic dose): NAC may slightly reduce paracetamol's analgesic efficacy by accelerating GSH-mediated clearance. Effect is small at supplement NAC doses; clinically negligible.

• GCLC, GCLM (glutamate-cysteine ligase subunits): Encode the rate-limiting enzyme in GSH synthesis. Polymorphisms affect basal GSH levels and supplementation response. GCLM -588 C/T variant is associated with reduced GSH synthesis capacity; carriers may benefit more from cysteine supplementation. No clinically actionable dosing guideline yet.
• GSTM1, GSTT1, GSTP1 (glutathione-S-transferase isoforms): Null-deletion polymorphisms (GSTM1*0/0, GSTT10/*0) reduce GSH-conjugation capacity. ~20-40% of populations carry one or both null deletions. Carriers theoretically benefit more from GSH-precursor supplementation. Not an actionable dose adjustment.
• CDO1, CTH (cysteine catabolism): Affect cysteine→taurine vs cysteine→GSH partitioning. Could in theory shift NAC's downstream effects but no direct supplementation data.
• MTHFR variants: Affect homocysteine metabolism, which intersects with cysteine via cystathionine. MTHFR C677T TT carriers have higher homocysteine and theoretical disturbance of sulfur amino acid balance — NAC may help restore the cysteine pool. No actionable dosing change.
• 23andMe relevance for Dylan (results ~June 5-15, 2026): Worth checking GCLM -588, GSTM1, GSTT1, MTHFR. None will likely change the 1200 mg/day dose, but if a pattern of low-GSH-capacity variants emerges, the rationale for keeping NAC daily strengthens further. If MTHFR TT, also reinforces the case for B-vitamin support to keep homocysteine in check.

Recommended for Dylan: Continue Swanson NAC via iHerb (current V4). No change. Cost is trivially small. Quality is reliable. Already integrated into the iHerb monthly order.

• Baseline (before starting):

  • Liver panel: ALT, AST, GGT (NAC is liver-friendly; GGT is the most sensitive marker of hepatocyte oxidative stress and responds to NAC)
  • hsCRP (inflammation)
  • Optional / advanced: whole-blood or RBC glutathione (specialty labs); plasma cysteine; oxidized LDL; MDA (malondialdehyde)
  • Homocysteine (transsulfuration pathway intersects with cysteine)
  • Lipid panel (NAC modestly improves in metabolic-syndrome populations)

• During use (every 6-12 months):

  • Liver panel — looking for stable or improved GGT, ALT, AST
  • hsCRP — looking for ↓ or stable
  • Optional: GSH (RBC), homocysteine — look for stable cysteine pool
  • Subjective: rumination / obsessive-thought score; post-sparring brain-fog scale; cold/illness frequency

• Post-cycle: N/A — not cycled.

For Dylan specifically: tie this into the June 2026 baseline panel he already has scheduled. GGT + ALT + hsCRP are the high-value markers. No additional bloodwork needed solely for NAC. NfL (neurofilament light) and S100B are emerging biomarkers of subconcussive impact damage; if accessible via specialty panel, baseline + 6-month is worth doing for Dylan independent of NAC, and would also serve as the closest thing to a personal NAC efficacy readout for the brain-protection thesis.